Excellent outcomes in children and adolescents with CNS Burkitt lymphoma or other mature B-NHL using only intrathecal and systemic chemoimmunotherapy: results from FAB/LMB96 and COG ANHL01P1.
作者信息
Frazer J Kimble, Li Kevin J, Galardy Paul J, Perkins Sherrie L, Auperin Anne, Anderson James R, Pinkerton Ross, Buxton Allen, Gross Thomas G, Michon Jean, Leverger Guy, Weinstein Howard J, Harrison Lauren, Shiramizu Bruce, Barth Mathew J, Goldman Stanton C, Patte Catherine, Cairo Mitchell S
机构信息
Paediatric Hematology-Oncology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA.
Paediatric Hematology-Oncology, Mayo Clinic, Rochester, MN, USA.
出版信息
Br J Haematol. 2019 Apr;185(2):374-377. doi: 10.1111/bjh.15520. Epub 2018 Aug 16.
Abstract
摘要
相似文献
1
Excellent outcomes in children and adolescents with CNS Burkitt lymphoma or other mature B-NHL using only intrathecal and systemic chemoimmunotherapy: results from FAB/LMB96 and COG ANHL01P1.仅使用鞘内和全身化学免疫疗法治疗中枢神经系统伯基特淋巴瘤或其他成熟B细胞非霍奇金淋巴瘤的儿童和青少年患者取得了优异疗效：来自FAB/LMB96和儿童肿瘤协作组ANHL01P1研究的结果
Br J Haematol. 2019 Apr;185(2):374-377. doi: 10.1111/bjh.15520. Epub 2018 Aug 16.
2
Rituximab with chemotherapy in children and adolescents with central nervous system and/or bone marrow-positive Burkitt lymphoma/leukaemia: a Children's Oncology Group Report.利妥昔单抗联合化疗治疗中枢神经系统和/或骨髓阳性的儿童及青少年伯基特淋巴瘤/白血病：儿童肿瘤学组报告
Br J Haematol. 2014 Nov;167(3):394-401. doi: 10.1111/bjh.13040. Epub 2014 Jul 26.
3
Results of a randomized international study of high-risk central nervous system B non-Hodgkin lymphoma and B acute lymphoblastic leukemia in children and adolescents.一项针对儿童和青少年高危中枢神经系统B细胞非霍奇金淋巴瘤及B细胞急性淋巴细胞白血病的随机国际研究结果。
Blood. 2007 Apr 1;109(7):2736-43. doi: 10.1182/blood-2006-07-036665.
4
Treatment of newly diagnosed B-cell origin primary CNS lymphoma with systemic R-IDARAM chemotherapy and intrathecal immunochemotherapy.采用全身R-IDARAM化疗和鞘内免疫化疗治疗新诊断的B细胞起源原发性中枢神经系统淋巴瘤。
Oncotarget. 2016 May 3;7(18):25783-90. doi: 10.18632/oncotarget.8370.
5
Treatment of relapsed/refractory paediatric aggressive B-cell non-Hodgkin lymphoma.儿童复发/难治性侵袭性 B 细胞非霍奇金淋巴瘤的治疗。
Br J Haematol. 2020 Jun;189(5):826-843. doi: 10.1111/bjh.16461. Epub 2020 Mar 6.
6
Optimal dosage of rituximab for children with Burkitt lymphoma.美罗华（利妥昔单抗）治疗儿童伯基特淋巴瘤的最佳剂量。
Ann Hematol. 2024 Mar;103(3):893-903. doi: 10.1007/s00277-023-05568-w. Epub 2023 Dec 13.
7
Treatment outcome in children with central nervous system-positive Burkitt lymphoma using only intrathecal and systemic chemotherapy combined with rituximab.仅采用鞘内和全身化疗联合利妥昔单抗治疗中枢神经系统阳性伯基特淋巴瘤患儿的治疗结果。
Chin Med J (Engl). 2021 Mar 17;134(11):1329-1334. doi: 10.1097/CM9.0000000000001386.
8
Efficacy of the GMALL-B-ALL/NHL2002 protocol in Burkitt leukemia/lymphoma and aggressive non-Hodgkin-lymphomas with or without CNS involvement.GMALL-B-ALL/NHL2002 方案在伴或不伴 CNS 累及的伯基特白血病/淋巴瘤和侵袭性非霍奇金淋巴瘤中的疗效。
Eur J Haematol. 2019 Mar;102(3):241-250. doi: 10.1111/ejh.13199. Epub 2019 Jan 20.
9
Mature B-cell lymphoma and leukemia in children and adolescents-review of standard chemotherapy regimen and perspectives.儿童和青少年成熟B细胞淋巴瘤及白血病——标准化疗方案综述与展望
Pediatr Hematol Oncol. 2013 Sep;30(6):465-83. doi: 10.3109/08880018.2013.783891. Epub 2013 Apr 9.
10
Intrathecal methotrexate prophylaxis and central nervous system relapse in patients with diffuse large B-cell lymphoma following rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone.利妥昔单抗联合环磷酰胺、阿霉素、长春新碱和泼尼松治疗的弥漫性大B细胞淋巴瘤患者鞘内注射甲氨蝶呤预防中枢神经系统复发
Leuk Lymphoma. 2015 Mar;56(3):725-9. doi: 10.3109/10428194.2014.931953. Epub 2014 Aug 6.
引用本文的文献
1
Association of the expression of Th1/Th2 cytokines and lymphocyte subsets with clinical characteristics and outcomes in 207 Chinese children with Burkitt's lymphoma.207例中国儿童伯基特淋巴瘤患者中Th1/Th2细胞因子表达及淋巴细胞亚群与临床特征和预后的相关性
Chin Med J (Engl). 2024 Aug 20;137(16):2011-2013. doi: 10.1097/CM9.0000000000003059. Epub 2024 Mar 21.
2
Optimal dosage of rituximab for children with Burkitt lymphoma.美罗华（利妥昔单抗）治疗儿童伯基特淋巴瘤的最佳剂量。
Ann Hematol. 2024 Mar;103(3):893-903. doi: 10.1007/s00277-023-05568-w. Epub 2023 Dec 13.
3
Co-Occurrence of Pallister-Killian Syndrome and Burkitt Lymphoma in a Patient with Near-Normal Neurocognitive Development.一名神经认知发育接近正常的患者同时患有帕利斯特-基利安综合征和伯基特淋巴瘤。
Mol Syndromol. 2023 Aug;14(4):303-309. doi: 10.1159/000530197. Epub 2023 May 5.
4
Targeting MYC-driven lymphoma: lessons learned and future directions.靶向MYC驱动的淋巴瘤：经验教训与未来方向。
Cancer Drug Resist. 2023 Apr 12;6(2):205-222. doi: 10.20517/cdr.2022.127. eCollection 2023.
5
Prognostic factors for adult patients with Burkitt lymphoma treated with dose-adjusted EPOCH-R.接受剂量调整的EPOCH-R方案治疗的成年伯基特淋巴瘤患者的预后因素
Blood Adv. 2023 Sep 26;7(18):5320-5324. doi: 10.1182/bloodadvances.2023010223.
6
Management of Aggressive Non-Hodgkin Lymphomas in the Pediatric, Adolescent, and Young Adult Population: An Adult vs. Pediatric Perspective.儿童、青少年及青年人群侵袭性非霍奇金淋巴瘤的管理：成人视角与儿童视角对比
Cancers (Basel). 2022 Jun 13;14(12):2912. doi: 10.3390/cancers14122912.
7
Clinical characteristics and treatment outcomes of children and adolescents with aggressive mature B-cell lymphoma: a single-center analysis.侵袭性成熟B细胞淋巴瘤儿童及青少年的临床特征与治疗结果：一项单中心分析
Blood Res. 2022 Mar 31;57(1):41-50. doi: 10.5045/br.2021.2021164.
8
Sequential different B-cell antigen-targeted CAR T-cell therapy for pediatric refractory/relapsed Burkitt lymphoma.序贯不同 B 细胞抗原靶向 CAR T 细胞疗法治疗儿科难治/复发伯基特淋巴瘤。
Blood Adv. 2022 Feb 8;6(3):717-730. doi: 10.1182/bloodadvances.2021004557.
9
Treatment outcome in children with central nervous system-positive Burkitt lymphoma using only intrathecal and systemic chemotherapy combined with rituximab.仅采用鞘内和全身化疗联合利妥昔单抗治疗中枢神经系统阳性伯基特淋巴瘤患儿的治疗结果。
Chin Med J (Engl). 2021 Mar 17;134(11):1329-1334. doi: 10.1097/CM9.0000000000001386.
10
Obinutuzumab (GA101) vs. rituximab significantly enhances cell death, antibody-dependent cytotoxicity and improves overall survival against CD20+ primary mediastinal B-cell lymphoma (PMBL) in a xenograft NOD-scid IL2Rgnull (NSG) mouse model: a potential targeted agent in the treatment of PMBL.在异种移植NOD-scid IL2Rgnull（NSG）小鼠模型中，奥滨尤妥珠单抗（GA101）与利妥昔单抗相比，可显著增强细胞死亡、抗体依赖性细胞毒性，并提高针对CD20+原发性纵隔B细胞淋巴瘤（PMBL）的总生存率：一种治疗PMBL的潜在靶向药物。
Oncotarget. 2020 Aug 11;11(32):3035-3047. doi: 10.18632/oncotarget.27691.
本文引用的文献
1
Overall survival of children and adolescents with mature B cell non-Hodgkin lymphoma who had refractory or relapsed disease during or after treatment with FAB/LMB 96: A report from the FAB/LMB 96 study group.FAB/LMB 96 方案治疗期间或治疗后发生难治或复发的成熟 B 细胞非霍奇金淋巴瘤患儿和青少年的总生存：来自 FAB/LMB 96 研究组的报告。
Br J Haematol. 2018 Sep;182(6):859-869. doi: 10.1111/bjh.15491. Epub 2018 Jul 9.
2
Outcome of and prognostic factors for relapse in children and adolescents with mature B-cell lymphoma and leukemia treated in three consecutive prospective "Lymphomes Malins B" protocols. A Société Française des Cancers de l'Enfant study.在三项连续的前瞻性“Lymphomes Malins B”方案中接受治疗的成熟B细胞淋巴瘤和白血病儿童及青少年复发的结局及预后因素。法国儿童癌症协会的一项研究。
Haematologica. 2015 Jun;100(6):810-7. doi: 10.3324/haematol.2014.121434. Epub 2015 Feb 27.
3
Rituximab with chemotherapy in children and adolescents with central nervous system and/or bone marrow-positive Burkitt lymphoma/leukaemia: a Children's Oncology Group Report.利妥昔单抗联合化疗治疗中枢神经系统和/或骨髓阳性的儿童及青少年伯基特淋巴瘤/白血病：儿童肿瘤学组报告
Br J Haematol. 2014 Nov;167(3):394-401. doi: 10.1111/bjh.13040. Epub 2014 Jul 26.
4
Advanced stage, increased lactate dehydrogenase, and primary site, but not adolescent age (≥ 15 years), are associated with an increased risk of treatment failure in children and adolescents with mature B-cell non-Hodgkin's lymphoma: results of the FAB LMB 96 study.晚期、乳酸脱氢酶升高以及原发部位，但不是青少年年龄（≥15 岁），与成熟 B 细胞非霍奇金淋巴瘤患儿和青少年治疗失败风险增加相关：FAB LMB 96 研究结果。
J Clin Oncol. 2012 Feb 1;30(4):387-93. doi: 10.1200/JCO.2010.33.3369. Epub 2012 Jan 3.
5
Excellent survival following two courses of COPAD chemotherapy in children and adolescents with resected localized B-cell non-Hodgkin's lymphoma: results of the FAB/LMB 96 international study.接受两疗程COPAD化疗的儿童和青少年切除性局限性B细胞非霍奇金淋巴瘤患者生存率极佳：FAB/LMB 96国际研究结果
Br J Haematol. 2008 Jun;141(6):840-7. doi: 10.1111/j.1365-2141.2008.07144.x. Epub 2008 Mar 26.
6
Prevalence, clinical pattern, and outcome of CNS involvement in childhood and adolescent non-Hodgkin's lymphoma differ by non-Hodgkin's lymphoma subtype: a Berlin-Frankfurt-Munster Group Report.儿童和青少年非霍奇金淋巴瘤中枢神经系统受累的患病率、临床模式及转归因非霍奇金淋巴瘤亚型而异：柏林-法兰克福-明斯特集团报告
J Clin Oncol. 2007 Sep 1;25(25):3915-22. doi: 10.1200/JCO.2007.11.0700.
7
Results of a randomized international study of high-risk central nervous system B non-Hodgkin lymphoma and B acute lymphoblastic leukemia in children and adolescents.一项针对儿童和青少年高危中枢神经系统B细胞非霍奇金淋巴瘤及B细胞急性淋巴细胞白血病的随机国际研究结果。
Blood. 2007 Apr 1;109(7):2736-43. doi: 10.1182/blood-2006-07-036665.
8
Results of the randomized international FAB/LMB96 trial for intermediate risk B-cell non-Hodgkin lymphoma in children and adolescents: it is possible to reduce treatment for the early responding patients.针对儿童和青少年中危B细胞非霍奇金淋巴瘤的随机国际FAB/LMB96试验结果：对于早期反应患者有可能减少治疗。
Blood. 2007 Apr 1;109(7):2773-80. doi: 10.1182/blood-2006-07-036673.
Zotero 插件